JP4874985B2 - 免疫調節化合物による出血性ウイルス感染の治療又は予防 - Google Patents
免疫調節化合物による出血性ウイルス感染の治療又は予防 Download PDFInfo
- Publication number
- JP4874985B2 JP4874985B2 JP2007539137A JP2007539137A JP4874985B2 JP 4874985 B2 JP4874985 B2 JP 4874985B2 JP 2007539137 A JP2007539137 A JP 2007539137A JP 2007539137 A JP2007539137 A JP 2007539137A JP 4874985 B2 JP4874985 B2 JP 4874985B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- fever
- composition
- tryptophan
- hemorrhagic fever
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 22
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 8
- 230000002008 hemorrhagic effect Effects 0.000 title abstract description 8
- 230000009385 viral infection Effects 0.000 title abstract description 6
- 238000011282 treatment Methods 0.000 title description 14
- 230000002265 prevention Effects 0.000 title description 4
- 108010049353 golotimod Proteins 0.000 claims description 36
- CATMPQFFVNKDEY-YPMHNXCESA-N Golotimod Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-YPMHNXCESA-N 0.000 claims description 35
- 241000700605 Viruses Species 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 15
- 206010023927 Lassa fever Diseases 0.000 claims description 14
- 208000003829 American Hemorrhagic Fever Diseases 0.000 claims description 9
- 241000712898 Machupo mammarenavirus Species 0.000 claims description 6
- 241000192617 Sabia mammarenavirus Species 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 208000005989 Arenaviridae Infections Diseases 0.000 claims description 5
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 claims description 5
- 241000190708 Guanarito mammarenavirus Species 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 claims description 4
- 201000010424 Brazilian hemorrhagic fever Diseases 0.000 claims description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229930182827 D-tryptophan Chemical group 0.000 claims description 3
- 241000712890 Junin mammarenavirus Species 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 2
- 201000009693 Venezuelan hemorrhagic fever Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 206010061192 Haemorrhagic fever Diseases 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 241000712891 Arenavirus Species 0.000 description 10
- 208000034158 bleeding Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- -1 aromatic amino acid Chemical group 0.000 description 7
- 206010012310 Dengue fever Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
- 241001115402 Ebolavirus Species 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 4
- 241000150528 Dobrava-Belgrade orthohantavirus Species 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 241000712902 Lassa mammarenavirus Species 0.000 description 4
- 241001115401 Marburgvirus Species 0.000 description 4
- 241000150452 Orthohantavirus Species 0.000 description 4
- 241000713124 Rift Valley fever virus Species 0.000 description 4
- 208000009714 Severe Dengue Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000025729 dengue disease Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 241000150489 Andes orthohantavirus Species 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000150488 Bayou orthohantavirus Species 0.000 description 2
- 241000150523 Black Creek Canal orthohantavirus Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000150547 Laguna Negra orthohantavirus Species 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- 241000168432 New York hantavirus Species 0.000 description 2
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 2
- 241000982791 Oran virus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000013544 Platelet disease Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 241000710772 Yellow fever virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000024597 arenavirus hemorrhagic fever Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 2
- 201000009892 dengue shock syndrome Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940051021 yellow-fever virus Drugs 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000190598 Flexal mammarenavirus Species 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000030156 Marburg disease Diseases 0.000 description 1
- 241001223933 Mastomys sp. Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Chemical group 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000712910 Pichinde mammarenavirus Species 0.000 description 1
- 101710188315 Protein X Chemical group 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000736032 Sabia <angiosperm> Species 0.000 description 1
- 241000150278 Seoul orthohantavirus Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 108010054509 gamma-glutamyltryptophan Proteins 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
[発明の分野]
本発明は、出血性ウイルス感染の治療又は予防の分野に関する。
本出願は、2004年10月27日に出願された米国仮特許出願第60/622,022号の利益を主張し、これは本明細書中に援用される。
出血熱ウイルス(HFV)は、幾つかの分類群に分類されるウイルスである。HFVは、急性出血熱症候群と称される、類似の臨床的特徴を伴う多様な疾病症候群を引き起こす。HFV感染の病態生理学的特徴は、微小血管障害及び血管透過性の増大である。RNAウイルスであるHFVとしては、ラッサウイルス、並びにフニンウイルス、マチュポウイルス、グアナリトウイルス、及びサビアウイルスを含む南アメリカ出血熱ウイルス(これらはそれぞれ、ラッサ熱、アルゼンチン出血熱、ボリビア出血熱、ベネズエラ出血熱、及びブラジル出血熱の病原体である)、ホワイトウォーター・アロヨウイルス、及びフレキサル(Flexal)ウイルス等のアレナウイルス科;フィロウイルス科(エボラウイルス及びマールブルグウイルス);ブニアウイルス科:クリミア−コンゴ出血熱ウイルス(CCHFV)、リフトバレー熱ウイルス、腎症候群関連のハンタウイルス(これには、ハンターンウイルス、ソウルウイルス、ドブラバウイルス(ドブラバ−ベオグラードウイルスとも称される)、及びプーマラウイルスが含まれる)による出血熱ウイルス、並びにハンタウイルス肺症候群関連のハンタウイルス(これには、バイユーウイルス、ブラック・クリーク・キャナルウイルス、ニューヨークウイルス、シンノンブルウイルス、アンデスウイルス、オランウイルス、ジュキチバ(Juquitiba)ウイルス、ラグナネグラ(Laguna Negra)ウイルス、及びレチグアナスウイルスが含まれる);並びにフラビウイルス科(デング、デング熱、デング出血熱、デング熱ショック症候群、キャサヌール森林病、オムスク出血熱、及び黄熱病)が挙げられる。
本発明によれば、被検体におけるアレナウイルス感染を治療もしくは予防するための組成物であって、式A:
一実施形態によれば、本発明は被検体に免疫調節化合物を投与することによる出血性ウイルス感染の治療又は予防に関する。
SCV−07すなわちγ−D−グルタミル−L−トリプトファンは、γ−グルタミル部又はβ−アスパルチル部を有する免疫調節剤群の成員であり、これはロシアの科学者によって発見され、SciClone Pharmaceuticals, Inc.により米国で幾つかの症状に対する有効性が試験されている。SCV−07は、インビボ及びインビトロで多くの免疫調節活性を有している。SCV−07はCon−A誘導胸腺細胞を増加させ、リンパ細胞の増殖を高め、Con−A誘導インターロイキン−2(IL−2)の生成及び脾臓リンパ細胞によるIL−2レセプターの発現を高めて、骨髄細胞におけるThy−1.2の発現を刺激する。インビボでは、SCV−07は、5−FU免疫抑制動物及びヒツジの赤血球による免疫付与モデルにおける免疫刺激性の効果が強い。
20個体の雄のハートレーモルモット(400〜450g)を5個体ずつ群に分けた。
0群には、SCV−07を与えなかった。
1群には、感染前の5日間、毎日、1μg/kgのSCV−07を腹腔内において与えた。
2群には、感染と同じ日に1度、1μg/kgのSCV−07を腹腔内において与えた。
3群には、感染の1日後に1度、1μg/kgのSCV−07を腹腔内において与えた。
再び20個体の動物を5個体ずつ4群に分けた。
0群には、SCV−07を与えなかった。
4群には、感染後、初めの5日間、毎日、腹腔内において1μg/kgのSCV−07を与えた。
5群には、感染後、初めの5日間、毎日、腹腔内において10μg/kgのSCV−07を与えた。
6群には、感染後、初めの5日間、毎日、腹腔内において100μg/kgのSCV−07を与えた。
Claims (9)
- 前記化合物がγ−D−グルタミル−L−トリプトファンである、請求項1に記載の組成物。
- 前記化合物が、約0.1〜10mgの範囲内の用量で投与される、請求項1に記載の組成物。
- 前記化合物が、約0.1〜1mgの範囲内の用量で投与される、請求項1に記載の組成物。
- 前記化合物が、被検体の体重1kg当たり約0.01〜100μgの範囲内の用量で投与される、請求項1に記載の組成物。
- 前記化合物が、被検体の体重1kg当たり約0.1〜10μgの範囲内の用量で投与される、請求項1に記載の組成物。
- 前記化合物がγ−D−グルタミル−L−トリプトファンである、請求項6に記載の組成物。
- 前記アレナウイルス感染が、ラッサ熱ウイルス、フニンウイルス、マチュポウイルス、グアナリトウイルスまたはサビアウイルスによる感染である、請求項1に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62202204P | 2004-10-27 | 2004-10-27 | |
US60/622,022 | 2004-10-27 | ||
PCT/US2005/038834 WO2006047702A2 (en) | 2004-10-27 | 2005-10-27 | Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008518031A JP2008518031A (ja) | 2008-05-29 |
JP4874985B2 true JP4874985B2 (ja) | 2012-02-15 |
Family
ID=36228480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007539137A Expired - Fee Related JP4874985B2 (ja) | 2004-10-27 | 2005-10-27 | 免疫調節化合物による出血性ウイルス感染の治療又は予防 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8193152B2 (ja) |
EP (1) | EP1814566B1 (ja) |
JP (1) | JP4874985B2 (ja) |
KR (1) | KR20070070202A (ja) |
CN (1) | CN101048171B (ja) |
AT (1) | ATE475426T1 (ja) |
AU (1) | AU2005299609A1 (ja) |
BR (1) | BRPI0517401A (ja) |
CA (1) | CA2585457A1 (ja) |
DE (1) | DE602005022612D1 (ja) |
EA (1) | EA012342B1 (ja) |
ES (1) | ES2350087T3 (ja) |
IL (1) | IL182710A (ja) |
MX (1) | MX2007005092A (ja) |
NO (1) | NO20072498L (ja) |
NZ (1) | NZ555322A (ja) |
SG (1) | SG163601A1 (ja) |
UA (1) | UA92727C2 (ja) |
WO (1) | WO2006047702A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116053A1 (en) * | 2005-04-22 | 2006-11-02 | Sciclone Pharmaceuticals, Inc. | Immunomodulator compounds as vaccine enhancers |
UA96980C2 (ru) | 2007-02-13 | 2011-12-26 | Сайклон Фармасютикалс, Инк. | Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки |
CA2826875A1 (en) * | 2011-02-09 | 2012-08-16 | Sciclone Pharmaceuticals, Inc. | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527065A (ja) * | 1997-12-25 | 2001-12-25 | ティー. ウェイ,エドワード | 免疫調節化合物を含有するγ−グルタミルおよびβ−アスパルチルおよびそれを用いた方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744452A (en) * | 1995-11-28 | 1998-04-28 | Edward T. Wei | γ-L-glutamyl containing immunomodulator compounds and methods therewith |
KR20070012522A (ko) | 2004-05-14 | 2007-01-25 | 사이클론 파아머슈티컬 인코오퍼레이티드 | 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방 |
UA12948U (en) | 2005-07-11 | 2006-03-15 | Inst Of Veterinary Medicine Uk | Associated inactivated concentrated serdosan vaccine against colibacteriosis, edematous disease, pasteurellosis, salmonellosis, and anaerobic enterotoxicemia of pigs |
-
2005
- 2005-10-27 DE DE602005022612T patent/DE602005022612D1/de active Active
- 2005-10-27 BR BRPI0517401-5A patent/BRPI0517401A/pt not_active IP Right Cessation
- 2005-10-27 EA EA200700878A patent/EA012342B1/ru not_active IP Right Cessation
- 2005-10-27 CN CN2005800369890A patent/CN101048171B/zh not_active Expired - Fee Related
- 2005-10-27 WO PCT/US2005/038834 patent/WO2006047702A2/en active Application Filing
- 2005-10-27 CA CA002585457A patent/CA2585457A1/en not_active Abandoned
- 2005-10-27 AT AT05813862T patent/ATE475426T1/de not_active IP Right Cessation
- 2005-10-27 JP JP2007539137A patent/JP4874985B2/ja not_active Expired - Fee Related
- 2005-10-27 KR KR1020077010092A patent/KR20070070202A/ko not_active Application Discontinuation
- 2005-10-27 AU AU2005299609A patent/AU2005299609A1/en not_active Abandoned
- 2005-10-27 MX MX2007005092A patent/MX2007005092A/es active IP Right Grant
- 2005-10-27 US US11/577,645 patent/US8193152B2/en not_active Expired - Fee Related
- 2005-10-27 UA UAA200705421A patent/UA92727C2/ru unknown
- 2005-10-27 SG SG201005002-9A patent/SG163601A1/en unknown
- 2005-10-27 EP EP05813862A patent/EP1814566B1/en active Active
- 2005-10-27 NZ NZ555322A patent/NZ555322A/en not_active IP Right Cessation
- 2005-10-27 ES ES05813862T patent/ES2350087T3/es active Active
-
2007
- 2007-04-22 IL IL182710A patent/IL182710A/en not_active IP Right Cessation
- 2007-05-15 NO NO20072498A patent/NO20072498L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527065A (ja) * | 1997-12-25 | 2001-12-25 | ティー. ウェイ,エドワード | 免疫調節化合物を含有するγ−グルタミルおよびβ−アスパルチルおよびそれを用いた方法 |
Also Published As
Publication number | Publication date |
---|---|
DE602005022612D1 (de) | 2010-09-09 |
NO20072498L (no) | 2007-05-15 |
US20090143313A1 (en) | 2009-06-04 |
IL182710A0 (en) | 2007-07-24 |
NZ555322A (en) | 2009-02-28 |
WO2006047702A3 (en) | 2006-07-20 |
IL182710A (en) | 2012-04-30 |
KR20070070202A (ko) | 2007-07-03 |
CA2585457A1 (en) | 2006-05-04 |
EP1814566A2 (en) | 2007-08-08 |
BRPI0517401A (pt) | 2008-10-14 |
JP2008518031A (ja) | 2008-05-29 |
ATE475426T1 (de) | 2010-08-15 |
ES2350087T3 (es) | 2011-01-18 |
US8193152B2 (en) | 2012-06-05 |
CN101048171A (zh) | 2007-10-03 |
EA012342B1 (ru) | 2009-10-30 |
EA200700878A1 (ru) | 2007-10-26 |
EP1814566B1 (en) | 2010-07-28 |
MX2007005092A (es) | 2007-07-04 |
WO2006047702A2 (en) | 2006-05-04 |
SG163601A1 (en) | 2010-08-30 |
CN101048171B (zh) | 2011-02-09 |
AU2005299609A1 (en) | 2006-05-04 |
EP1814566A4 (en) | 2008-05-07 |
UA92727C2 (ru) | 2010-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Enria et al. | Treatment of Argentine hemorrhagic fever | |
FR3057773A1 (fr) | Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus | |
PT2627334E (pt) | Composições para utilização no tratamento de infeções virais | |
KR100290132B1 (ko) | 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체 | |
Wilson et al. | Diseases of the central nervous system caused by lymphocytic choriomeningitis virus and other arenaviruses | |
JP4874985B2 (ja) | 免疫調節化合物による出血性ウイルス感染の治療又は予防 | |
JPH0725702B2 (ja) | ディルチアゼムおよびアンギオテンシン変換酵素阻害剤を含有する医薬組成物 | |
IL237119A (en) | Heterocyclic carboxamides for the treatment of viral diseases | |
JP2007537280A (ja) | 免疫調節性化合物を用いる呼吸器のウイルス感染の治療又は予防 | |
JP7399976B2 (ja) | Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 | |
US20230233538A1 (en) | Composition for treating coronavirus disease-19, comprising phenanthroindolizidine and phenanthroquinolizidine alkaloid derivatives, optical isomer thereof, or pharmaceutically acceptable salts thereof as active ingredient | |
ES2371635T3 (es) | Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes. | |
KR101045985B1 (ko) | 아릴 디케토산(adk) 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물 | |
TWI272947B (en) | Pharmaceutical compositions for suppressing influenza virus infection and replication | |
JP6469568B2 (ja) | グルタチオンを含有する免疫増強剤 | |
RU2814927C1 (ru) | Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту, лекарственное средство, ее содержащее, а также их применение для лечения и/или профилактики вирусных инфекций | |
Peter et al. | Murine Models for Development of Anti-Infective Therapeutics | |
BR112013013526B1 (pt) | uso de pacap para o tratamento de infecções virais em organismos aquáticos, e combinação veterinária | |
JP6656670B2 (ja) | 抗hcv活性を有する薬剤 | |
Caroleo et al. | Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation | |
WO2022005848A1 (en) | Combinations of carnosine and zinc for the treatment and prevention of viral infections | |
Enria | Arenaviral hemorrhagic fevers: Argentine hemorrhagic fever and Lassa fever | |
Peter et al. | Infective Therapeutics | |
Lutwick et al. | 3 Arenaviruses and Neurovirology | |
Gill et al. | Fatal acute pancreatitis in a patient chronically treated with candesartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111108 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111124 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141202 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |